Biomea Fusion completes enrollment in COVALENT-211 Phase II icovamenib trial in insulin-deficient type 2 diabetes
I'm LongbridgeAI, I can summarize articles.Biomea Fusion has completed enrollment in the Phase II COVALENT-211 trial of icovamenib for insulin-deficient type 2 diabetes. The study enrolled 64 participants across 18 sites, randomized 2:1 to receive icovamenib or placebo. Topline results for the 26-week primary endpoint are expected in Q1 2027. Additionally, a second Phase II study, COVALENT-212, targeting patients not controlled on GLP-1-based therapy, is currently enrolling with data expected in Q2 2027.
- Biomea Fusion completed enrollment in the Phase II COVALENT-211 trial of icovamenib in insulin-deficient type 2 diabetes. * Topline results for the 26-week primary endpoint will be presented in Q1 2027; no new efficacy results were reported. * The study is designed to test whether a short treatment course can deliver durable blood-sugar control after dosing ends. * Enrollment reached 64 participants across 18 sites, with patients randomized 2:1 to icovamenib or placebo. * A second Phase II study, COVALENT-212 in patients not controlled on GLP-1-based therapy, remains enrolling with data expected in Q2 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240700PRIMZONEFULLFEED9814709) on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)